ArticleNeuropsychiatric disease and treatment2026
Clinical Efficacy of Integrated Acupuncture and Moxibustion Therapy Combined with Drugs in the Treatment of Acute Depressive Disorder: Protocol for a Pragmatic Randomized Controlled Trial.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Escitalopram oxalate is a first-line pharmacological treatment for acute-phase depressive disorder, but delayed onset and adverse effects may compromise adherence and early treatment response. Adjunctive non-pharmacological therapies are commonly used in clinical practice. This study aims to evaluate the efficacy and safety of integrative acupuncture and moxibustion combined with escitalopram oxalate in patients with moderate depressive disorder during the acute phase. Methods: This is a single-center, open-label, pragmatic, randomized clinical trial. A total of 300 participants with moderate depressive disorder will be randomly assigned in a 1:1:1 ratio to three groups: escitalopram oxalate alone, escitalopram oxalate plus repetitive transcranial magnetic stimulation (rTMS), or escitalopram oxalate plus integrative acupuncture and moxibustion (iAM) (100 participants per group). All participants will receive escitalopram oxalate, while adjunctive rTMS will be administered five times weekly for 3 weeks and iAM three times weekly for 6 weeks. Outcome Measures: The primary outcome is the Hamilton Depression Rating Scale. Secondary outcomes include liver and kidney function, Stanford Expectations of Treatment Scale, Beck Depression Inventory-II, Generalized Anxiety Disorder-7, Hamilton Anxiety Scale, and Insomnia Severity Index. Conclusion: This trial will assess whether iAM combined with escitalopram oxalate is a feasible, safe, and potentially effective adjunctive treatment for moderate depressive disorder during the acute phase. The findings are expected to provide clinical evidence for the use of iAM in routine depression care. Trial Registration: ITMCTR2024000380 (International Traditional Medicine Clinical Trial Registry; registered on 05 Sep 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.